Morgan Stanley lowered the firm’s price target on Insulet to $208 from $343 and keeps an Equal Weight rating on the shares after updating its model following Q2 results. Though the firm recognizes “it’s still early in the debate,” it has lowered out-year estimates in light of recent GLP-1 data releases that limit visibility into the business’s long-term growth trajectory.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PODD: